Acetaminophen is so ordinary a remedy that its danger is easy to overlook, yet it remains the leading cause of liver failure in the United States, and the doctors who treat that failure have long worked from memory and inference rather than certainty. Researchers in Little Rock have built a quick blood test that may finally offer a plain answer to the question of whether this common medicine was the cause. The work now rests on a federal grant and a multicenter trial, and whether that answer reaches emergency rooms will depend on what that trial shows and what regulators decide.
New 20-Minute Blood Test Could Rapidly Identify Acetaminophen-Induced Liver Injury
No FDA-approved test confirms acetaminophen liver injury. This one takes 20 minutes.
Mark
So what's the actual problem this test is trying to solve?
Mimi
Doctors can't confirm that acetaminophen caused a liver injury. There's no FDA-approved test for it. They lean on what the patient says and on liver tests that show damage but not the cause.
Mark
And acetaminophen is a big player here?
Mimi
It's the most common cause of liver failure in the US, and the most common drug for pain and fever.
Luke
Before we get carried away, has this been proven? The 20-minute figure is the reporting's headline claim.
Mimi
The test has been used in earlier testing, and the grant exists to run the multicenter trial that will evaluate its performance. So the formal proof is still ahead.
Luke
Right. The praise comes from the inventor and a co-investigator, both people invested in it. Nothing here gives accuracy numbers.
Mark
What does Dr. Lee say he values?
Mimi
A reliable yes/no answer on whether acetaminophen is responsible. He wants it in emergency departments everywhere.
Luke
That's his hope and his impression, not a trial result. And FDA approval is not guaranteed; Dr. James is optimistic, not certain.
Mark
So what should we watch?
Mimi
The trial results, then the FDA decision. The grant runs three years and totals $3.2 million.
Der Puls
- Acetaminophen is everywhere in homes, yet no FDA-approved test can confirm when it has injured the liver.
- Emergency physicians are left reconstructing overdoses from patient accounts and nonspecific liver tests that show damage but not its source.
- A 20-minute blood assay called AcetaSTAT promises a yes-or-no answer, and its inventors are pressing toward regulatory review.
- A $3.2 million NIH grant is funding a multicenter trial, and the test's fate now hinges on those results and the FDA's decision.
Acetaminophen is so ordinary a remedy that its danger is easy to overlook, yet it remains the leading cause of liver failure in the United States, and the doctors who treat that failure have long worked from memory and inference rather than certainty. Researchers in Little Rock have built a quick blood test that may finally offer a plain answer to the question of whether this common medicine was the cause. The work now rests on a federal grant and a multicenter trial, and whether that answer reaches emergency rooms will depend on what that trial shows and what regulators decide.
Acetaminophen is the drug people reach for first when pain or fever arrives, and it is also the leading cause of liver failure in the United States. When a patient comes in with liver injury from an overdose, doctors have no FDA-approved test that confirms the drug is responsible. They depend on what the patient says was taken, alongside blood tests that reveal the liver is damaged without explaining why.
At the University of Arkansas for Medical Sciences in Little Rock, researchers have developed AcetaSTAT, a rapid assay that detects blood markers of acetaminophen-related liver injury in about 20 minutes. It is described as the first rapid diagnostic test for acetaminophen toxicity. The National Institutes of Health has awarded the inventors a three-year, $3.2 million grant to finish development as a laboratory test and to run a clinical trial across several centers before they seek FDA approval.
Laura James, M.D., one of the inventors, calls the project a long journey that has been both fun and exciting, and she is hopeful about its prospects given how it has performed so far. William M. Lee, M.D., a liver specialist at UT Southwestern who co-investigates the trial, says he has been impressed by its reliable yes-or-no answer and hopes to see it in emergency departments worldwide, where more patients could receive the correct diagnosis and treatment.
For now, the path forward runs through the multicenter trial and then the FDA's judgment. Only those results will show whether a 20-minute answer can reach the emergency room.
Acetaminophen is the most common drug people reach for when they have pain or a fever. In the United States it is also the leading cause of liver failure. Yet when a patient arrives with liver injury from an overdose, doctors have no FDA-approved test that confirms acetaminophen is the culprit.
What they have instead is the patient's account of what was taken, along with blood tests that show the liver is damaged but do not say why. Those tests are nonspecific. The diagnosis rests on history and inference.
Researchers at the University of Arkansas for Medical Sciences in Little Rock have now developed a test meant to close that gap. Called AcetaSTAT, it is a rapid assay that detects blood markers of acetaminophen-related liver injury in about 20 minutes. It is described as the first rapid diagnostic test for acetaminophen toxicity.
The work is moving toward its last stage. The National Institutes of Health has awarded the test's inventors a three-year grant of $3.2 million to carry out the final phase of study before they seek approval from the Food and Drug Administration. The money covers the final development of AcetaSTAT as a laboratory test, and a clinical trial at multiple centers to evaluate how it performs.
Laura James, M.D., of UAMS, is one of the test's inventors. She called the project a long journey, but a fun and exciting one, because it is heading toward a significant contribution to health care. She is optimistic about the assay's chances of winning FDA approval, pointing to how it has performed so far.
William M. Lee, M.D., a liver disease specialist at the University of Texas Southwestern Medical Center at Dallas, is a co-investigator on the trial and has taken part in earlier testing of the assay. He said he has been impressed that it gives a reliable yes-or-no answer on whether acetaminophen is responsible for a patient's liver injury. He hopes to see AcetaSTAT in emergency departments worldwide, and said that having the test would mean more patients get the right diagnosis and appropriate treatment.
What happens next depends on the multicenter trial. Its results, and then the FDA's decision, will determine whether a 20-minute answer ever reaches the emergency department.
Bemerkenswerte Zitate
The assay provides a reliable yes/no answer as to whether acetaminophen is responsible for the liver injury.— William M. Lee, M.D., UT Southwestern Medical Center
It has been a long journey, but it has been fun and exciting because we're moving toward a big contribution in health care.— Laura James, M.D., UAMS
Möchten Sie die ganze Geschichte?
Das Original lesen bei HospiMedica ↗
Health & Medicine